Ribonuclease Inhibitor: Structure and Function

Progress in Nucleic Acid Research and Molecular Biology

Volumn 80, Issue , 2005, Pages 349-374

  Dickson, Kimberly A ^a   Haigis, Marcia C ^a   Raines, Ronald T ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTEINE; ENZYME INHIBITOR; MULTIPROTEIN COMPLEX; RIBONUCLEASE;

AMINO ACID SEQUENCE; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; HUMAN; METABOLISM; MOLECULAR EVOLUTION; MOLECULAR GENETICS; OXIDATION REDUCTION REACTION; PROTEIN CONFORMATION; REVIEW; SEQUENCE HOMOLOGY;

AMINO ACID SEQUENCE; ANIMALS; CYSTEINE; ENZYME INHIBITORS; EVOLUTION, MOLECULAR; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; MULTIPROTEIN COMPLEXES; OXIDATION-REDUCTION; PROTEIN CONFORMATION; RIBONUCLEASES; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 27344444248     PISSN: 00796603     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0079-6603(05)80009-1     Document Type: Review

References (128)

1. Roth J.S. Some observations on the assay and properties of ribonucleases in normal and tumor tissues. In: Busch H. (Ed). "Methods in Cancer Research" (1967), Academic Press, New York 153-242
2. Blackburn P., and Moore S. Pancreatic ribonuclease. The Enzymes XV (1982) 317-433
3. Lee F.S., and Vallee B.L. Structure and action of mammalian ribonuclease (angiogenin) inhibitor. Prog. Nucl. Acid Res. Molec. Biol. 44 (1993) 1-30
4. Hofsteenge J. Ribonuclease inhibitor. In: D'Alessio G., and Riordan J.F. (Eds). "Ribonucleases: Structures and Functions" (1997), Academic Press, New York 621-658
5. Shapiro R. Cytoplasmic ribonuclease inhibitor. Methods Enzymol. 341 (2001) 611-628
6. Kobe B., and Deisenhofer J. Crystal structure of porcine ribonuclease inhibitor, a protein with leucine-rich repeats. Nature 366 (1993) 751-756
7. Hofsteenge J., Kieffer B., Matthies R., Hemmings B.A., and Stone S.R. Amino acid sequence of the ribonuclease inhibitor from porcine liver reveals the presence of leucine-rich repeats. Biochemistry 27 (1988) 8537-8544
8. Lee F.S., Fox E.A., Zhou H.-M., Strydom D.J., and Vallee B.L. Primary structure of human placental ribonuclease inhibitor. Biochemistry 27 (1988) 8545-8553
9. Janin J. Proteins with a ring. Structure 2 (1994) 571-573
10. Kobe B., and Deisenhofer J. The leucine-rich repeat: A versatile binding motif. Trends Biochem. Sci. 19 (1994) 415-421
11. Shapiro R., Riordan J.F., and Vallee B.L. LRRning the Rite of springs. Nat. Struct. Biol. 2 (1995) 350-354
12. Kobe B., and Kajava A.V. The leucine-rich repeat as a protein recognition motif. Curr. Opin. Struct. Biol. 11 (2001) 725-732
13. Pasloske B.L. Ribonuclease inhibitors. In: Schein C.H. (Ed). "Nuclease Methods and Protocols" (2001), Humana Press, Totowa, New Jersey 105-111
14. Youle R.J., and D'Alessio G. Antitumor RNases. In: D'Alessio G., and Riordan J.F. (Eds). "Ribonucleases: Structures and Functions" (1997), Academic Press, New York 491-514
15. Leland P.A., and Raines R.T. Cancer chemotherapy-Ribonucleases to the rescue. Chem. Biol. 8 (2001) 405-413
16. Matoušek J. Ribonucleases and their antitumor activity. Comp. Biochem. Physiol. C. Toxicol. Pharmacol. 129 (2001) 175-191
17. Makarov A.A., and Ilinskaya O.N. Cytotoxic ribonucleases: Molecular weapons and their targets. FEBS Lett. 540 (2003) 15-20
18. Moroianu J., and Riordan J.F. Nuclear translocation of angiogenin in proliferating endothelial cells is essential to its angiogenic activity. Proc. Natl. Acad. Sci. USA 91 (1994) 1677-1681
19. Xu Z.P., Tsuji T., Riordan J.F., and Hu G.F. The nuclear function of angiogenin in endothelial cells is related to rRNA production. Biochem. Biophys. Res. Commun. 294 (2003) 287-292
20. Fominaya J.M., and Hofsteenge J. Inactivation of ribonuclease inhibitor by thiol-disulfide exchange. J. Biol. Chem. 267 (1992) 24655-24660
21. Pirotte M., and Desreux V. Distribution de la ribonuclease dans les extraits de granules cellulaires du foie. Bull. Soc. Chem. Belg. 61 (1952) 167
22. Roth J.S. Ribonuclease IX. Further studies on ribonuclease inhibitor. Biochim. Biophys. Acta 61 (1962) 903-915
23. Blackburn P., Wilson G., and Moore S. Ribonuclease inhibitor from human placenta. Purification and properties. J. Biol. Chem. 252 (1977) 5904-5910
24. Burton L.E., Blackburn P., and Moore S. Ribonuclease inhibitor from bovine brain. Int. J. Peptide Protein Res. 16 (1980) 359-364
25. Cho S., and Joshi J.G. Ribonuclease inhibitor from pig brain: Purification, characterization, and direct spectrophotometric assay. Anal. Biochem. 176 (1989) 175-181
26. Nadano D., Yasuda T., Takeshita H., Uchide K., and Kishi K. Purification and characterization of human brain ribonuclease inhibitor. Arch. Biochem. Biophys. 312 (1994) 421-428
27. Gribnau A.A., Schoenmakers J.G., van Kraaikamp M., and Bloemendal H. High purification of the RNase inhibitor from rat liver by affinity chromatography. Biochem. Biophys. Res. Commun. 38 (1970) 1064-1068
28. Burton L.E., and Fucci N.P. Ribonuclease inhibitors from the liver of five mammalian species. Int. J. Peptide Protein Res. 19 (1982) 372-379
29. Ferreras M., Gavilanes J.G., López-Otín C., and García-Segura J.M. Thiol-disulfide exchange of ribonuclease inhibitor bound to ribonuclease A. Evidence of active inhibitor-bound ribonuclease. J. Biol. Chem. 270 (1995) 28570-28578
30. Moenner M., Vosoghi M., Ryazantsev S., and Glitz D.G. Ribonuclease inhibitor protein of human erythrocytes: Characterization, loss of activity in response to oxidative stress, and association with Heinz bodies. Blood Cells Mol. Dis. 24 (1998) 149-164
31. Raines R.T. Ribonuclease A. Chem. Rev. 98 (1998) 1045-1065
32. Garcia M.A., and Klebe R.J. Affinity chromatography of RNase inhibitor. Mol. Biol. Rep. 24 (1997) 231-233
33. Blackburn P. Ribonuclease inhibitor from human placenta: Rapid purification and assay. J. Biol. Chem. 254 (1979) 12484-12487
34. Vescia S., Tramontano D., Augusti-Tocco G., and D'Alessio G. In vitro studies on selective inhibition of tumor cell growth by seminal ribonuclease. Cancer Res. 40 (1980) 3740-3744
35. Lee F.S., and Vallee B.L. Expression of human placental ribonuclease inhibitor in Escherichia coli. Biochem. Biophys. Res. Commun. 160 (1989) 115-120
36. Vicentini A.M., Kieffer B., Mathies R., Meyhack B., Hemmings B.A., Stone S.R., and Hofsteenge J. Protein chemical and kinetic characterization of recombinant porcine ribonuclease inhibitor expressed in Saccharomyces cerevisiae. Biochemistry 29 (1990) 8827-8834
37. Klink T.A., Vicentini A.M., Hofsteenge J., and Raines R.T. High-level soluble production and characterization of porcine ribonuclease inhibitor. Protein Expr. Purif. 22 (2001) 174-179
38. Blackburn P., and Jailkhan B.L. Ribonuclease inhibitor from human placenta: Interaction with derivatives of ribonuclease A. J. Biol. Chem. 254 (1979) 12488-12493
39. Kawanomoto M., Motojima K., Sasaki M., Hattori H., and Goto S. cDNA cloning and sequence of rat ribonuclease inhibitor, and tissue distribution of mRNA. Biochim. Biophys. Acta 1129 (1992) 335-338
40. Haigis M.C., Haag E.S., and Raines R.T. Evolution of ribonuclease inhibitor by exon duplication. Mol. Biol. Evol. 19 (2002) 959-963
41. Lee F.S., Shapiro R., and Vallee B.L. Tight-binding inhibition of angiogenin and ribonuclease A by placental ribonuclease inhibitor. Biochemistry 28 (1989) 225-230
42. Green N.M. Avidin. Adv. Protein Chem. 29 (1975) 85-133
43. Zelenko O., Neumann U., Brill W., Pieles U., Moser H.E., and Hofsteenge J. A novel fluorogenic substrate for ribonucleases. Synthesis and enzymatic characterization. Nucleic Acids Res. 22 (1994) 2731-2739
44. Boix E., Wu Y., Vasandani V.M., Saxena S.K., Ardelt W., Ladner J., and Youle R.J. Role of the N terminus in RNase A homologues: Differences in catalytic activity, ribonuclease inhibitor interaction, and cytotoxicity. J. Mol. Biol. 257 (1996) 992-1007
45. Hofsteenge J., Vicentini A., and Zelenko O. Ribonuclease 4, an evolutionarily highly conserved member of the superfamily. Cell. Mol. Life Sci. 54 (1998) 804-810
46. Lee F.S., Auld D.S., and Vallee B.L. Tryptophan fluorescence as a probe of placental ribonuclease inhibitor binding to angiogenin. Biochemistry 28 (1989) 219-224
47. Shapiro R., and Vallee B.L. Interaction of human placental ribonuclease with placental ribonuclease inhibitor. Biochemistry 30 (1991) 2246-2255
48. Abel R.L., Haigis M.C., Park C., and Raines R.T. Fluorescence assay for the binding of ribonuclease A to the ribonuclease inhibitor protein. Anal. Biochem. 306 (2001) 100-107
49. Haigis M.C., Kurten E.L., Abel R.L., and Raines R.T. KFERQ sequence in ribonuclease A-mediated cytotoxicity. J. Biol. Chem. 277 (2002) 11576-11581
50. Dickson K.A., Dahlberg C.L., and Raines R.T. Compensating effects on the cytotoxicity of ribonuclease A variants. Archives Biochem. Biophys. 415 (2003) 172-177
51. Kobe B., and Deisenhofer J. A structural basis of the interactions between leucine-rich repeats and protein ligands. Nature 374 (1995) 183-186
52. Kajava A.V. Structural diversity of leucine-rich repeat proteins. J. Mol. Biol. 277 (1998) 519-527
53. Takahashi N., Takahashi Y., and Putnam F.W. Periodicity of leucine and tandem repetition of a 24-amino acid segment in the primary structure of leucine-rich alpha 2-glycoprotein of human serum. Proc. Natl. Acad. Sci. USA 82 (1985) 1906-1910
54. Kobe B., and Deisenhofer J. Proteins with leucine-rich repeats. Curr. Opin. Struct. Biol. 5 (1995) 409-416
55. Price S.R., Evans P.R., and Nagai K. Crystal structure of the spliceosomal U2B″-U2A′ protein complex bound to a fragment of U2 small nuclear RNA. Nature 394 (1998) 645-650
56. Evdokimov A.G., Anderson D.E., Routzahn K.M., and Waugh D.S. Unusual molecular architecture of the Yersinia pestis cytotoxin YopM: A leucine-rich repeat protein with the shortest repeating unit. J. Mol. Biol. 312 (2001) 807-821
57. Schulman B.A., Carrano A.C., Jeffrey P.D., Bowen Z., Kinnucan E.R., Finnin M.S., Elledge S.J., Harper J.W., Pagano M., and Pavletich N.P. Insights into SCF ubiquitin ligases from the structure of the Skp1-Skp2 complex. Nature 408 (2000) 381-386
58. Matteo A.D., Federici L., Mattei B., Salvi G., Johnson K.A., Savino C., Lorenzo G.D., and Tsernoglou D. The crystal structure of polygalacturonase-inhibiting protein (PGIP), a leucine-rich repeat protein involved in plant defense. Proc. Natl. Acad. Sci. USA 100 (2003) 10124-10128
59. Schott P.G., McEwan P.A., Dodd C.M., Bergmann E.M., Bishop P.N., and Bella J. Crystal structure of the dimeric protein core of decorin, the archetypal small leucine-rich repeat proteoglycan. Proc. Natl. Acad. Sci. USA 101 (2004) 15633-15638
60. Stumpp M.T., Forrer P., Binz H.K., and Pluckthun A. Designing repeat proteins: Modular leucine-rich repeat protein libraries based on mammalian ribonuclease inhibitor family. J. Mol. Biol. 332 (2003) 471-487
61. Crawford D., Hagerty K., and Beutler B. Multiple splice forms of ribonuclease-inhibitor mRNA differ in the 5′-untranslated region. Gene 85 (1989) 525-531
62. Schneider R., Schneider-Scherzer E., Thurnher M., Auer B., and Schweiger M. The primary structure of human ribonuclease/angiogenin inhibitor (RAI) discloses a novel highly diversified protein superfamily with a common repetitive module. EMBO J. 7 (1988) 4151-4156
63. Kajava A.V., and Kobe B. Assessment of the ability to model proteins with leucine-rich repeats in light of the latest structural information. Protein Sci. 11 (2002) 1082-1090
64. Lee F.S., and Vallee B.L. Modular mutagenesis of human placental ribonuclease inhibitor, a protein with leucine-rich repeats. Proc. Natl. Acad. Sci. USA 87 (1990) 1879-1883
65. Hofsteenge J., Vincentini A., and Stone S.R. Purification and characterization of truncated ribonuclease inhibitor. Biochem. J. 275 (1991) 541-543
66. Kraft N., and Shortman K. The phylogeny of the ribonuclease-ribonuclease inhibitor system: Its distribution in tissues and its response during leukaemogenesis and aging. Aust. J. Biol. Sci. 23 (1970) 175-184
67. Wlodawer A. Structure of bovine pancreatic ribonuclease by X-ray and neutron diffraction. In: Jurnak F.A., and McPherson A. (Eds). "Biological Macromolecules and Assemblies, Vol. II, Nucleic Acids and Interactive Proteins" (1985), Wiley, New York 395-439
68. Kobe B., and Deisenhofer J. Mechanism of ribonuclease inhibition by ribonuclease inhibitor protein based on the crystal structure of its complex with RNase A. J. Mol. Biol. 264 (1996) 1028-1043
69. Papageorgiou A.C., Shapiro R., and Acharya K.R. Molecular recognition of human angiogenin by placental ribonuclease inhibitor-An X-ray crystallographic study at 2.0 Å resolution. EMBO J. 16 (1997) 5162-5177
70. Chen C.-Z., and Shapiro R. Superadditive and subadditive effects of "hot spot" mutations within the interfaces of placental ribonuclease inhibitor with angiogenin and ribonuclease A. Biochemistry 38 (1999) 9273-9285
71. Leland P.A., Schultz L.W., Kim B.-M., and Raines R.T. Ribonuclease A variants with potent cytotoxic activity. Proc. Natl. Acad. Sci. USA 98 (1998) 10407-10412
72. Crick F.H.C. Is α-keratin a coiled coil?. Nature 170 (1952) 882-883
73. Chen C.-Z., and Shapiro R. Site-specific mutagenesis reveals differences in the structural bases for tight binding of RNase inhibitor to angiogenin and RNase A. Proc. Natl. Acad. Sci. USA 94 (1997) 1761-1766
74. Shapiro R., Ruiz-Gutierrez M., and Chen C.-Z. Analysis of the interactions of human ribonuclease inhibitor with angiogenin and ribonuclease A by mutagenesis: Importance of inhibitor residues inside versus outside the C-terminal "hot spot.". J. Mol. Biol. 302 (2000) 497-519
75. Teufel D.P., Kao R.Y.T., Acharya K.R., and Shapiro R. Mutational analysis of the complex of human RNase inhibitor and human eosinophil-derived neurotoxin. Biochemistry 42 (2003) 1451-1459
76. Kumar K., Brady M., and Shapiro R. Selective abolition of pancreatic RNase binding to its inhibitor protein. Proc. Natl. Acad. Sci. USA 101 (2004) 53-58
77. Kim B.-M., Schultz L.W., and Raines R.T. Variants of ribonuclease inhibitor that resist oxidation. Protein Sci. 8 (1999) 430-434
78. Blázquez M., Fominaya J.M., and Hofsteenge J. Oxidation of sulfhydryl groups of ribonuclease inhibitor in epithelial cells is sufficient for its intracellular degradation. J. Biol. Chem. 271 (1996) 18638-18642
79. Futami J., Tsushima Y., Murato Y., Tada H., Sasaki J., Seno M., and Yamada H. Tissue-specific expression of pancreatic-type RNases and RNase inhibitor in humans. DNA Cell. Biol. 16 (1997) 413-419
80. Wojnar R.J., and Roth J.S. Ribonuclease inhibitor and latent ribonuclease in rat liver during feeding of 2-acetamidofluorene. Cancer Res. 25 (1965) 1913-1918
81. Suzuki Y., and Takahashi Y. Developmental and regional variations in ribonuclease inhibitor activity in brain. J. Neurochem. 17 (1970) 1521-1524
82. Kyner D., Christman J.K., and Acs G. The effect of 12-O-tetradecanoyl-phorbol 13-acetate on the ribonuclease activity of circulating human lymphocytes. Eur. J. Biochem. 99 (1979) 395-399
83. Botella-Estrada R., Malet G., Revert F., Dasi F., Crespo A., Sanmartin O., Guillen C., and Alino S.F. Antitumor effect of B16 melanoma cells genetically modified with the angiogenesis inhibitor rnasin. Cancer Gene Ther. 8 (2001) 278-284
84. Ledoux L. Action of ribonuclease on certain ascites tumors. Nature 175 (1955) 258-259
85. Ledoux L. Action of ribonuclease on two solid tumors in vivo. Nature 176 (1955) 36-37
86. Roth J.S. Ribonuclease activity and cancer: A review. Cancer Res. 23 (1963) 657-666
87. Matoušek J. The effect of bovine seminal ribonuclease (AS RNase) on cells of crocker tumor in mice. Experientia 29 (1973) 858-859
88. Matoušek J. Aspermatogenic effect of the bull seminal ribonuclease (BS RNase) in the presence of anti BS RNase antibodies in mice. Animal Genet. 25 Suppl. 1 (1994) 45-50
89. Matoušek J. Embryotoxic effect of bull seminal ribonuclease and tissue absorption studies in rats. J. Reprod. Fertil. 43 (1975) 171-174
90. Slavík T., Matoušek J., Fulka J., and Raines R.T. Effect of bovine seminal ribonuclease and bovine pancreatic ribonuclease A on bovine oocyte maturation. J. Exp. Zool. 287 (2000) 394-399
91. Matoušek J., Souček J., Ríha J., Zankel T.R., and Benner S.A. Immunosuppressive activity of angiogenin in comparison with bovine seminal ribonuclease and pancreatic ribonuclease. Comp. Biochem. Physiol. 112B (1995) 235-241
92. Darzynkiewicz Z., Carter S.P., Mikulski S.M., Ardelt W.J., and Shogen K. Cytostatic and cytotoxic effect of Pannon (P-30 Protein), a novel anticancer agent. Cell Tissue Kinet. 21 (1988) 169-182
93. Nitta K., Takayanagi G., Kawauchi H., and Hakomori S. Isolation and characterization of Rana catesbeiana lectin and demonstration of the lectin-binding glycoprotein of rodent and human tumor cell membranes. Cancer Res. 47 (1987) 4877-4883
94. Nitta K., Ozaki K., Ishikawa M., Furusawa S., Hosono M., Kawauchi H., Sasaki K., Takayanagi Y., Tsuiki S., and Hakomori S. Inhibition of cell proliferation by Rana catesbeiana and Rana japonica lectins belonging to the ribonuclease superfamily. Cancer Res. 54 (1994) 920-927
95. Ardelt W., Mikulski S.M., and Shogen K. Amino acid sequence of an anti-tumor protein from Rana pipiens oocytes and early embryos. J. Biol. Chem. 266 (1991) 245-251
96. Mikulski S.M., Ardelt W., Shogen K., Bernstein E.H., and Menduke H. Striking increase of survival of mice bearing M109 Madison carcinoma treated with a novel protein from amphibian embryos. J. Natl. Cancer Inst. 82 (1990) 151-153
97. ® (P-30 Protein) administered intravenously on a weekly schedule in cancer patients with solid tumors. Int. J. Oncol. 3 (1993) 57-64
98. ® with other anticancer agents. Int. J. Oncol. 6 (1995) 889-897
99. Mikulski S.M., Costanzi J.J., Vogelzang N.J., McCachren S., Taub R.N., Chun H., Mittelman A., Panella T., Puccio C., Fine R., and Shogen K. Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J. Clin. Oncol. 20 (2002) 274-281
100. Bretscher L.E., Abel R.L., and Raines R.T. A ribonuclease A variant with low catalytic activity but high cytotoxicity. J. Biol. Chem. 275 (2000) 9893-9896
101. Leland P.A., Staniszewski K.E., Kim B., and Raines R.T. A synapomorphic disulfide bond is critical for the conformational stability and cytotoxicity of an amphibian ribonuclease. FEBS Lett. 477 (2000) 203-207
102. Wu Y., Mikulski S.M., Ardelt W., Rybak S.M., and Youle R.J. A cytotoxic ribonuclease. J. Biol. Chem. 268 (1993) 10686-10693
103. Newton D.L., Xue Y., Boque L., Wlodawer A., Kung H.F., and Rybak S.M. Expression and characterization of a cytotoxic human-frog chimeric ribonuclease: Potential for cancer therapy. Protein Eng. 10 (1997) 463-470
104. Newton D.L., Boque L., Wlodawer A., Huang C.Y., and Rybak S.M. Single amino acid substitutions at the N-terminus of a recombinant cytotoxic ribonuclease markedly influence biochemical and biological properties. Biochemistry 37 (1998) 5173-5183
105. Mosimann S.C., Ardelt W., and James M.N.G. Refined 1.7 Å X-ray crystallographic structure of P-30 protein, an amphibian ribonuclease with anti-tumor activity. J. Mol. Biol. 236 (1994) 1141-1153
106. Notomista E., Catanzano F., Graziano G., Di Gaetano S., Barone G., and Di Donato A. Contribution of chain termini to the conformational stability and biological activity of onconase. Biochemistry 40 (2001) 9097-9103
107. Leland P.A., Staniszewski K.E., Kim B.M., and Raines R.T. Endowing human pancreatic ribonuclease with toxicity for cancer cells. J. Biol. Chem. 276 (2001) 43095-43102
108. Haigis M.C., Kurten E.L., and Raines R.T. Ribonuclease inhibitor is an intracellular sentry. Nucleic Acids Res. 31 (2002) 1024-1032
109. Raines R.T. Ribonuclease A: From model system to cancer chemotherapeutic. In: Frey P.A., and Northrop D.B. (Eds). "Enzymatic Mechanisms" (1999), IOS Press, Washington, DC 235-249
110. Futami J., Nukui E., Maeda T., Kosaka M., Tada H., Seno M., and Yamada H. Optimum modification for the highest cytotoxicity of cationized ribonuclease. J. Biochem. (Tokyo) 132 (2002) 223-228
111. Monti D.M., and D'Alessio G. Cytosolic RNase inhibitor only affects RNases with intrinsic cytotoxicity. J. Biol. Chem. 279 (2004) 39195-39198
112. Strydom D.J. The angiogenins. Cell. Mol. Life Sci. 54 (1998) 811-824
113. Pavlov N., and Badet J. Angiogenin: Involvement in angiogenesis and tumor growth. Bull. Cancer 88 (2001) 725-732
114. Riordan J.F. Angiogenin. Methods Enzymol. 341 (2001) 263-273
115. Moroianu J., and Riordan J.F. Identification of the nucleolar targeting signal of human angiogenin. Biochem. Biophys. Res. Commun. 203 (1994) 1765-1772
116. Hu G.-F., Riordan J.F., and Vallee B.L. A putative angiogenin receptor in angiogenin-responsive human endothelial cells. Proc. Natl. Acad. Sci. USA 94 (1997) 2204-2209
117. Xu Z.-p., Tsuji T., Riordan J.F., and Hu G.-F. Identification and characterization of an angiogenin-binding DNA sequence that stimulates luciferase reporter gene expression. Biochemistry 42 (2003) 121-128
118. Harper J.W., and Vallee B.L. A covalent angiogenin/ribonuclease hybrid with a fourth disulfide bond generated by regional mutagenesis. Biochemistry 28 (1989) 1875-1884
119. Leland P.A., Staniszewski K.E., Park C., Kelemen B.R., and Raines R.T. The ribonucleolytic activity of angiogenin. Biochemistry 41 (2002) 1343-1350
120. Shapiro R., Fox E.A., and Riordan J.F. Role of lysines in human angiogenin: Chemical modification and site-directed mutagenesis. Biochemistry 28 (1989) 1726-1732
121. Shapiro R., and Riordan J.F. Site-directed mutagenesis of histidine-13 and histidine-114 of human angiogenin. Alanine derivatives inhibit angiogenin-induced angiogenesis. Biochemistry 28 (1989) 7401-7408
122. Shapiro R., and Vallee B.L. Human placental ribonuclease inhibitor abolishes both angiogenic and ribonucleolytic activities of angiogenin. Proc. Natl. Acad. Sci. USA 84 (1987) 2238-2241
123. Polakowski I.J., Lewis M.K., Muthukkaruppan V., Erdman B., Kubai L., and Auerbach R. A ribonuclease inhibitor expresses anti-angiogenic properties and leads to reduced tumor growth in mice. Am. J. Pathol. 143 (1993) 507-517
124. Dijkstra J., Touw J., Halsema I., Gruber M., and Ab G. Estradiol-induced synthesis of vitellogenin. Biochim. Biophys. Acta 521 (1978) 363-373
125. Cui X.Y., Fu P.F., Pan D.N., Zhao Y., Zhao J., and Zhao B.C. The antioxidant effects of ribonuclease inhibitor. Free Radic. Res. 37 (2003) 1079-1085
126. Allen D.W., and Jandl J.H. Oxidative hemolysis and precipitation of hemoglobin. II. Role of thiols in oxidant drug action. J. Clin. Invest. 40 (1961) 454-475
127. Cavalli L., Galaverni D., Pesando P., Bracchi P.G., Campanini G., and Maraini G. Control of ribonuclease activity in the human lens during aging and cataract formation. Ophthalmic Res. 11 (1979) 416-422
128. Kraft N., Shortman K., and Jamieson D. The effect of x-irradiation on the balance between alkaline ribonuclease and the ribonuclease inhibitor of mammalian tissues. Radiation Res. 39 (1969) 655-668